Advertisement
Screener

C4 Therapeutics, Inc. (CCCC) Graph

CCCC Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $6.64M; Research and development $24.47M; Operating expenses $33.06M; Income tax $0.00.
  • 2026-03-31: Revenue $6.15M; Research and development $24.61M; Operating expenses $33.94M; Income tax $0.00.
  • 2025-12-31: Revenue $11.02M*; Research and development $24.98M*; Operating expenses $34.16M*; Income tax $121.00K*.
  • 2025-09-30: Revenue $11.23M; Research and development $25.99M; Operating expenses $45.64M; Income tax $0.00.

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

CCCC revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Reportable Segment$0.00Revenue$6.64MOperating expenses$33.06MOperating income-$26.42MResearch & development$24.47MIncome tax$0.00Net income-$23.64M

Type Of Arrangement

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

CCCC revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Betta Agreement$15.00KBiogen Agreement$0.00MKDG Agreement$1.83MMerck Agreement$0.00Roche Agreement$2.13MRoche DAC Agreement$2.67MRevenue$6.64MOperating expenses$33.06MOperating income-$26.42MResearch & development$24.47MIncome tax$0.00Net income-$23.64M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$6.64M$24.47M$33.06M$0.00-$23.64M
2026-03-31$6.15M$24.61M$33.94M$0.00-$25.13M
2025-12-31$11.02M*$24.98M*$34.16M*$121.00K*-$20.49M*
2025-09-30$11.23M$25.99M$45.64M$0.00-$32.17M
2025-06-30$6.46M$26.20M$34.96M$0.00-$26.02M
2025-03-31$7.24M$27.07M$36.40M$0.00-$26.32M
2024-09-30$15.36M$31.84M$43.61M$0.00-$24.67M
2024-06-30$12.01M$23.75M$33.45M$0.00-$17.72M
2024-03-31$3.04M$22.53M$35.26M$0.00-$28.36M
2023-09-30$11.07M$28.35M$38.88M$1.00M-$27.04M
2023-06-30$2.66M$29.93M$40.23M$0.00-$35.92M
2023-03-31$3.76M$29.04M$39.99M$0.00-$34.78M
2022-09-30$6.75M$29.66M$39.24M$0.00-$31.96M
2022-06-30$13.83M$31.32M$41.22M(m)-$27.41M
2022-03-31$7.65M$26.20M$39.02M$0.00-$31.62M
2021-09-30$8.50M$24.30M$32.75M(m)-$24.68M
2021-06-30$9.78M$23.29M$31.90M(m)-$22.58M
2021-03-31(m)$20.53M$27.93M$0.00-$20.97M
2020-09-30(m)$23.93M$26.80M-$167.00K-$21.84M
2020-06-30(m)$17.76M$20.53M-$168.00K-$10.79M
2020-03-31(m)$16.31M$19.15M-$167.00K-$11.91M
2019-09-30(m)$12.95M$15.37M$650.00K-$10.09M

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$12.79M$49.08M$67.00M$0.00-$48.76M
2025-06-30$13.70M$53.27M$71.37M$0.00-$52.34M
2024-06-30$15.04M$46.29M$68.71M$0.00-$46.08M
2023-06-30$6.42M$58.97M$80.22M$0.00-$70.70M
2022-06-30$21.49M$57.53M$80.24M$0.00-$59.03M
2021-06-30$17.21M$43.81M$59.83M$0.00-$43.55M
2020-06-30(m)$34.07M$39.68M-$335.00K-$22.70M

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30$24.93M$79.26M$117.01M$0.00-$84.51M
2024-09-30$30.41M$78.12M$112.31M$0.00-$70.74M
2023-09-30$17.50M$87.31M$119.10M$1.00M-$97.74M
2022-09-30$28.24M$87.19M$119.48M$0.00-$90.99M
2021-09-30$25.71M$68.11M$92.59M$0.00-$68.23M
2020-09-30(m)$58.01M$66.48M-$502.00K-$44.54M
2019-09-30(m)$32.04M$38.13M$900.00K-$24.08M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$35.95M$104.24M$151.17M$121.00K-$104.99M
2024-12-31$35.58M$110.64M$155.20M$131.00K-$105.32M
2023-12-31$20.76M$117.71M$159.79M$1.28M-$132.49M
2022-12-31$31.10M$117.84M$160.63M$0.00-$128.18M
2021-12-31$45.78M$94.67M$127.92M$0.00-$83.89M
2020-12-31(m)$78.44M$93.64M-$626.00K-$66.33M
2019-12-31(m)$48.06M$56.83M$804.00K-$34.10M

Similar stocks

Stock NameCountryMarket CapPE Ratio
FENNEC PHARMACEUTICALS INC. (FENC)United States$0.371B-115.85
Artiva Biotherapeutics, Inc. (ARTV)United States$0.367B
Cabaletta Bio, Inc. (CABA)United States$0.365B-2.81
AGENUS INC (AGEN)United States$0.383B1.41
Surrozen, Inc./DE (SRZN)United States$0.395B
Zura Bio Ltd (ZURA)$0.398B-6.56
Ocugen, Inc. (OCGN)United States$0.343B-6.34
Scribe Therapeutics, Inc. (SCTX)United States$0.410B
Editas Medicine, Inc. (EDIT)United States$0.424B-4.29
Kyverna Therapeutics, Inc. (KYTX)United States$0.434B-3.60